Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, induces apoptosis in a variety of cancer cells with little or no effect on normal cells. Human hepatoma cells, however, are resistant to TRAIL-induced apoptosis. Since interferon-a (IFN-a) is capable of enhancing TNF-ainduced apoptosis in certain cancer cells, we evaluated the effect of IFN-a on TRAIL-induced apoptosis of human hepatoma cells. IFN-a pretreatment enhanced TRAILinduced apoptosis of HuH-7 and Hep3B cells, in which IFN-a upregulated the expression of DR5, a death receptor of TRAIL, and downregulated the expression of survivin, which has an antiapoptotic function. In contrast, IFN-a did not enhance TRAIL-induced apoptosis of HepG2 cells, in which expression of DR5 and survivin was not affected by IFN-a. On the other hand, TRAIL activated NF-jB composed of RelA-p50 heterodimer, a key transcription factor regulating cell survival, in HuH-7 and HepG2 cells. However, IFN-a pretreatment repressed the TRAIL-mediated activation of NF-jB and decreased its transcriptional activity in HuH-7 but not in HepG2 cells. Moreover, IFN-a pretreatment clearly augmented TRAIL-mediated caspase-8 activation in HuH-7 cells. Our results suggest that IFN-a could sensitize certain human hepatoma cells to TRAIL-induced apoptosis by stimulating its death signaling and by repressing the survival function in these cells.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a novel member of the TNF superfamily, is a promising candidate for cancer therapy since it preferentially induces apoptosis in a variety of cancer cells with little or no effect on normal cells (Sheridan et al., 1997; Ashkenazi et al., 1999; Walczak et al., 1999) . TRAIL triggers apoptosis through interaction with death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) (Pan et al., 1997; Schneider et al., 1997) , whereas TRAIL-R3, TRAIL-R4 and osteoprotegerin serve as decoy receptors to block TRAIL-mediated apoptosis (Degli-Esposti et al., 1997a, b; Emery et al., 1998) . DR4 and DR5 do not only signal apoptosis through Fas-associated death domain (FADD) and caspase-8 (Kischkel et al., 2000) , but also activate nuclear factor-kappaB (NF-kB), which regulates the expression of survival factors such as members of the inhibitor of apoptosis (IAP) family (c-IAP1, c-IAP2, XIAP) and Bcl-xL Chen et al., 2000) . These findings suggest the existence of several physiological mechanisms that protect normal cells against TRAIL-mediated apoptosis. Indeed, administration of recombinant TRAIL to experimental animals, including mice and primates, induced significant tumor regression without systemic toxicity (Ashkenazi et al., 1999; Walczak et al., 1999; Chinnaiyan et al., 2000) . In addition, a recent study revealed that recombinant TRAIL, trimerized through the endogenous cysteine residue at position 230, does not induce apoptosis of normal human hepatocytes (Lawrence et al., 2001) , which have been reported to be susceptible to the other type of recombinant TRAIL (Jo et al., 2000) . On the other hand, high concentrations of TRAIL are necessary to induce apoptosis of certain cancer cells, including human hepatoma cells . Thus, combinations of TRAIL with several chemotherapeutic agents or radiation have been evaluated for rendering such cells susceptible to TRAIL, and some combinations have successfully enhanced TRAILmediated cancer cell death (Chinnaiyan et al., 2000; Gibson et al., 2000; Nagane et al., 2000; Sun et al., 2000; Yamanaka et al., 2000; Zhou et al., 2000; Belka et al., 2001; Di Pietro et al., 2001; Lacour et al., 2001; Nimmanapalli et al., 2001) .
Interferon (IFN)-a/b plays an essential role in both antiviral and antitumor host defenses and has been used clinically for the treatment of viral infections and malignancies (Gutterman, 1994) . Several investigators have recently reported that IFN-a/b stimulates the expression of TRAIL in T cells or dendritic cells, resulting in upregulation of their cytotoxic activities (Fanger et al., 1999; Kayagaki et al., 1999) , and that the apoptosis observed in several cancer cells susceptible to IFN-a/b is mediated by induction of endogenous TRAIL in these cells (Chawla-Sarkar et al., 2001; Chen et al., 2001; Toomey et al., 2001) . Taken together, these findings suggest that IFN-a/b may, at least in part, exhibit its antitumor activity through induction of TRAIL. Conversely, IFN-a/b has been reported to sensitize human cervical cancer cells or Jurkat lymphoma cells to TNF-a-induced apoptosis through inhibition of NF-kB activation (Manna et al., 2000; Suk et al., 2001) . Since both TRAIL and TNF-a trigger death signaling and activate NF-kB Ravi et al., 2001) , we hypothesized that IFN-a/b could sensitize cancer cells to TRAIL-induced apoptosis. In the present study, we investigated whether IFN-a pretreatment could augment TRAIL-induced apoptosis of human hepatoma cells that exhibit resistance to TRAIL. In addition, we evaluated the effect of IFN-a on TRAIL-mediated activation of both caspase-8 and NF-kB, and also analysed whether IFN-a regulated the expression of TRAIL, DR4, DR5 and apoptosis-related proteins in these cells.
Results

IFN-a pretreatment sensitizes human hepatoma cells to TRAIL-induced apoptosis
To elucidate the effect of IFN-a on TRAIL-induced apoptosis of human hepatoma cells, HuH-7, HepG2, Hep3B and PLC/PRF/5 were preincubated with or without 1000 IU/ml of IFN-a for 48 h, followed by treatment with varying concentrations of TRAIL for 24 h. As shown in Figure 1 , TRAIL dose-dependently reduced cell viability of HuH-7 and HepG2, but higher concentrations of TRAIL were required to elicit significant cytotoxicity. Hep3B and PLC/PRF/5 were much more resistant to TRAIL-induced cytotoxicity. In contrast, preincubation with IFN-a enhanced the TRAIL-induced cytotoxicity in HuH-7, Hep3B and PLC/PRF/5, but not in HepG2, although IFN-a alone could reduce cell viability in PLC/PRF/5. Next, to examine whether IFN-a pretreatment actually enhanced TRAIL-induced apoptosis of HuH-7 and Hep3B, we examined the content of hypodiploid DNA in those cells. IFN-a pretreatment enhanced TRAIL-induced apoptosis of HuH-7 and Hep3B (Figure 2) . However, such enhancement was not observed in HepG2 cells. These results indicated that IFN-a sensitized HuH-7 and Hep3B, but not HepG2 cells, to TRAIL-induced apoptosis.
IFN-a upregulates DR5 expression and downregulates survivin expression in HuH-7 and Hep3B, but not in HepG2
Recent studies have shown that expression of death receptors, DR4 or DR5, is upregulated in cancer cells by chemotherapeutic agents or by radiation, resulting in enhancement of TRAIL-induced apoptosis of these cells (Gibson et al., 2000; Nagane et al., 2000; Sun et al., 2000; Zhou et al., 2000; Di Pietro et al., 2001; Lacour et al., 2001; Nimmanapalli et al., 2001) . We therefore examined the effect of IFN-a on expression of DR4 and DR5, as well as the expression of several apoptosisrelated proteins, including procaspase 8, FLICE-inhibitory protein (FLIP), CIAP2, XIAP, survivin, Bcl-xL and Bax, by Western blotting. As shown in Figure 3 , these proteins were constitutively expressed in HuH-7, HepG2 and Hep3B cells. DR5 expression was upregulated by IFN-a in HuH-7 and Hep3B but not in HepG2 cells. On the contrary, the expression of survivin, a member of the IAP family that has an antiapoptotic function, was repressed by IFN-a in HuH-7 and Hep3B but not in HepG2 cells. These results appeared to be parallel to the effect of IFN-a on TRAIL-induced apoptosis in these cells. Conversely, the expression of procaspase 8, FLIP and XIAP was almost unchanged, irrespective of the presence of IFN-a. DR4 expression (Figure 2 ). DR5 and DR4 expression on the cell membrane was also analysed by flow cytometry. As shown in Figure 4 , IFNa upregulated the surface expression of DR5 in HuH-7 and Hep3B but not in HepG2 cells. On the other hand, the surface expression of DR4 was slightly stimulated by IFN-a in HuH-7 but not in other cells. These results were almost similar to those of Western blotting. We next examined the effect of IFN-a on mRNA levels of TRAIL, DR4, DR5, survivin and several apoptosisrelated genes in HuH-7 cells by RNase protection assay ( Figure 5 ). IFN-a clearly upregulated the transcripts of DR5, and weakly stimulated the transcripts of DR4 and TRAIL, which appeared as faint bands (Figure 5a ). Procaspase 8 and CIAP2 mRNAs were also upregulated by IFN-a (Figure 5a and b) although this was not detectable by Western blotting (Figure 3 ). In contrast, survivin mRNA expression was repressed by IFN-a ( Figure 5b ).
To clarify the functional role of DR5 in enhancement of TRAIL-mediated apoptosis by IFN-a, we examined the effect of DR5-specific blocking chimera antibody on TRAIL/ IFN-a-induced apoptosis and also checked the impact of IFN-a on apoptosis triggered by DR5-specific agonistic antibody in HuH-7 cells. Addition of DR5-specific blocking chimera antibody dose-dependently inhibited TRAIL/ IFN-a-induced apoptosis of HuH-7 cells (Figure 6a ). In addition, IFN-a sensitized the cells to apoptosis induced by DR5-specific agonistic antibody ( Figure 6b ) as well as to apoptosis induced by TRAIL ( Figure 1 ). These results suggested that up-regulation of DR5 by IFN-a could contribute to enhanced TRAIL sensitivity in HuH-7 cells. Next, we also examined the involvement of survivin in resistance against TRAILmediated apoptosis of HuH-7 cells. In comparison with the vehicle vector transfection, transfection of the survivin expression vector which produced the flag/ survivin fusion protein ( Figure 7a ) partially but dosedependently inhibited TRAIL/IFN-a-induced apoptosis of HuH-7 cells (Figure 7b ). These results suggested that survivin might play a role in resistance against TRAILmediated apoptosis of HuH-7 cells.
IFN-a inhibits TRAIL-mediated NF-kB activation in HuH-7 but not in HepG2
Since TRAIL can both trigger death signaling and activate NF-kB, thus regulating the expression of several factors involved in cell survival, we examined the effect of IFN-a on TRAIL-mediated transcriptional activity of NF-kB in HuH-7 and HepG2 cells by reporter gene transfection assay. TRAIL dose-dependently stimulated luciferase activity from the plasmid pNFkB-luc (containing four repeats of NF-kB binding sequences) in both cells. However, IFN-a pretreatment suppressed this induction in HuH-7 but not in HepG2 cells (Figure 8 ). We then used EMSA to determine whether IFN-a could inhibit the TRAIL-mediated NFkB binding activity to oligonucleotides containing a NFkB binding (kB) sequence. Nuclear extracts from unstimulated HuH-7 cells formed a complex band with the oligonucleotide probe ( Figure 9a , lane 1). Addition In contrast, nuclear extract from HuH-7 cells preincubated with IFN-a for 48 h, followed by TRAIL treatment for 2 h did not form such a slowly migrating band (Figure 9b, lane 4) . These results indicated that TRAIL activated the NF-kB composed of RelA-p50 heterodimer in HuH-7, which was inhibited by IFN-a pretreatment. Such a slowly migrating band was also formed in HepG2 cells treated by TRAIL (which was not inhibited by IFN-a pretreatment) (Figure 9b , lanes 7 and 8), although similar supershifts were detected by addition of anti-p50 or anti-RelA (data not shown).
IFN-a enhances TRAIL-induced caspase-8 activity in HuH-7
Finally, we examined the effect of IFN-a on the TRAILmediated caspase-8 activity of cleaving IETD-pNAconjugated substrate. TRAIL time-dependently induced caspase-8 activity in HuH-7 cells. On the other hand, IFN-a pretreatment clearly enhanced its activity, which reached a peak level 4 hour after addition of TRAIL (Figure 10 ). 
Discussion
In this study, we have demonstrated that IFN-a pretreatment sensitized HuH-7 and Hep3B, but not HepG2, cells to TRAIL-induced apoptosis, and that IFN-a upregulated the expression of DR5 and downregulated the expression of survivin in HuH7 and Hep3B, but not in HepG2 cells. Recent studies have indicated that upregulation of DR5 by chemotherapeutic agents or radiation sensitizes many cancer cells to TRAIL-induced apoptosis through activation of death signaling (Gibson et al., 2000; Nagane et al., 2000; Sun et al., 2000; Zhou et al., 2000; Lacour et al., 2001; Nimmanapalli et al., 2001 ). In addition, we have shown that DR5-specific blocking chimera antibody inhibited TRAIL/ IFN-a-induced apoptosis in HuH-7 cells, and that IFN-a could sensitize the cells to apoptosis induced by DR5 specific agonistic antibody. Taken together, it seems that upregulation of DR5 by IFN-a enhances TRAIL sensitivity. Survivin, which is expressed in cancer tissues including hepatocellular carcinoma but not in normal tissues, represses the activities of caspases (Tamm et al., 1998; Ito et al., 2000) , resulting in resistance of cancer cells to Fas-or chemotherapeutic agent-mediated apoptosis (Li et al., 1998; Tamm et al., 1998) . In addition, inhibition of survivin expression, by transduction with antisense oligonucleotides or a dominant-negative expression vehicle, sensitized cancer cells to chemotherapeutic agent-mediated apoptosis (Olie et al., 2000; Grossman et al., 2001) . Recently, Griffith et al. (2002) (Figures 1 and 2) . The NF-kB transcription factor family consists of several structurally related proteins such as c-Rel, RelA, RelB, p50/p105, and p52/p100, which form homo-or heterodimers with each other and regulate the expression of a number of genes (Barkett and Gilmore, 1999) . In the present study, nuclear extracts from HuH-7 and HepG2 cells exhibited binding activity of NF-kB composed of a p50 homodimer without any stimulation, as reported in other types of cells (Inan et al., 2000) . TRAIL induced additional binding activity of NF-kB comprising a RelAp50 heterodimer in these cells. Ravi et al. (2001) have recently reported that RelA À/À mouse fibroblasts are highly sensitive to TRAIL-induced apoptosis, and that anti-CD40-mediated activation of NF-kB, including RelA, effectively blocked TRAIL-induced apoptosis. Therefore, NF-kB composed of RelA-p50 appears to play a key role in the resistance of HuH-7 and HepG2 cells to TRAIL-induced apoptosis. Indeed, IFN-a pretreatment inhibited TRAIL-mediated activation of RelA-p50 NF-kB in HuH-7 cells that were sensitized to TRAIL-induced apoptosis by IFN-a. In contrast, IFN-a pretreatment could not inhibit activated HepG2 cells that Figure 5 Effect of IFN-a on mRNA levels of DR4, DR5, TRAIL, pro-caspase 8 and IAP family genes in HuH-7 cells. HuH-7 cells were incubated with or without 1000 IU/ml of IFN-a for 48 h. Total RNA (10 mg) from the cells was subjected to analysis for mRNA levels of DR4, DR5, TRAIL, procaspase 8 and IAP family genes by RNase protection assay using human apoptosis multiprobe template sets, hAPO3-c (A) and hAPO-5c (B), respectively. Results shown are from one representative experiment from a total of three performed Enhancement of TRAIL-induced apoptosis by IFN-a M Shigeno et al remained resistant to TRAIL-induced apoptosis even in the presence of IFN-a. Similar observations have been reported where IFN-a suppressed activation of RelA-p50 NF-kB and potentiated TNF-a-induced apoptosis of human cervical cancer cells and Jurkat lymphoma cells (Manna et al., 2000; Suk et al., 2001) . Furthermore, Wen et al. (2000) have recently reported that overexpression of p202, an IFN-a-inducible protein, is capable of sensitizing breast cancer cells to TNF-a-induced apoptosis through inactivation of NF-kB by its interaction with p202. Taken together, these results indicate that IFN-a could possibly sensitize HuH-7 cells to TRAIL-induced apoptosis by inhibiting the activation of NF-kB including RelA. We also demonstrated that IFN-a stimulated TRAIL-mediated caspase-8 activity in HuH-7 cells, which could be explained by IFN-a-induced upregulation of DR5 in these cells. In addition, suppression of NF-kB activity by IFN-a may be also involved in the stimulation of caspase-8 activity, since the NF-kB-induced products, c-IAP, c-IAP2 and TNFR-associated factor-1 (TRAF1), are known to cooperatively block caspase-8 activity . However, why IFN-a did not inhibit NF-kB activity in HepG2 cells, even though IFN-a can stimulate the expression of IFN-a-inducible genes in HepG2 and HuH-7 cells (Ichikawa et al., 2001 ), remains to be clarified.
In conclusion, we have demonstrated in the present study that IFN-a potentiated the apoptotic effect of TRAIL in human hepatoma cells by regulating the expression of DR5 or survivin and by repressing TRAIL-mediated NF-kB activation. These results suggest that IFN-a may exhibit antitumor activity not only by endogenous TRAIL induction, but also by sensitizing cancer cells to TRAIL-mediated apoptosis, and that 
Materials and methods
Cell culture and detection of apoptosis
The human hepatoma cell lines, HepG2, Hep3B and PLC/ PRF/5 were maintained in a chemically defined medium, IS-RPMI (Nakabayashi et al., 1984) containing 10% fetal bovine serum (FBS). HuH-7 was maintained in IS-RPMI containing 5% FBS. Recombinant human TRAIL (leucine zipper construct) was supplied by Immunex Co. (Seattle, WA, USA). Recombinant human IFN-a 2a was provided by Nippon Roche Co. (Tokyo, Japan). To analyse cell viability, 5 Â 10 3 cells were placed into 96-well multiplates. A day later, the medium was replaced with fresh medium in the presence or absence of 1000 IU/ml of IFN-a, and the cells were incubated for 48 h, followed by treatment with varying concentrations of TRAIL for 24 h. In some experiments, varying concentrations of recombinant human TRAIL R2/Fc chimera, DR5-specific blocking chimera antibody (R&D systems, Minneapolis, MN, USA), or goat anti-human TRAIL R2/DR5 antibody, and a DR5-specific agonistic antibody (R&D systems), were added to the cell cultures. Cell viability was determined by the colorimetric method using a Cell Counting kit (Wako Life Science, Osaka, Japan). The absorbance of each well was measured at 405 nm with a microtiter plate reader (Multiskan JX, Thermo BioAnalysis Co., Japan). DNA fragmentation was quantified by the percentage of cells with hypodiploid DNA. In brief, cells were fixed with 70% ethanol and treated with RNase (100 mg/ml, Sigma Chemical Co., St Louis, MO, USA) and then stained with propidium iodide (100 mg/ml, Sigma) for 30 min on ice. The stained cells were analysed by a flow cytometer (Epics XL, Beckman Coulter, Hialeah, FL, USA) to detect the presence of cells with hypodiploid DNA.
Western blotting
Cells were washed three times with PBS, lysed by addition of lysis buffer (50 mm Tris (pH 8.0), 150 mm NaCl, 0.02% sodium azide, 0.1% SDS, 100 mg/ml PMSF, 1 mg/ml of aprotinin, 1% NP40, and 0.5% sodium deoxycholate) for 10 min at 41C and passed several times through a 25-gauge needle, and the protein concentration was determined using a Bio-Rad protein assay kit (Melville, NY, USA). The same amount of protein from each lysate (20 mg/well) was subjected to 8-16% SDS-PAGE. Proteins were transferred onto nitrocellulose membranes, that were then blocked for 1.5 h using 5% nonfat dried milk in PBS containing 0.1% Tween 20 (PBS-T), washed with PBS-T and incubated at room temperature for 1 h in the presence of each antibody (rabbit polyclonal anti-human DR4, Imgenex, San Diego, CA, USA; rabbit polyclonal anti-human DR5, R&D systems; mouse monoclonal anti-human caspase-8, MBL, Nagoya, Japan; rabbit polyclonal anti-human FLIP, PharMingen, San Diego, CA, USA; rabbit polyclonal antihuman Bax, Santa Cruz Biotechnology, Santa Cruz, CA, USA; mouse monoclonal anti-human Bcl-xL, Trevigen, Gaithersburg, MD, USA; mouse monoclonal anti-human XIAP, MBL; rabbit polyclonal anti-human survivin, Alpha Diagnostic International Inc., San Antonio, TX, USA; rabbit polyclonal anti-human c-IAP2, Santa Cruz Biotechnology; mouse monoclonal anti-flag antibody, Sigma; mouse monoclonal anti-human b-actin (as an internal control for Western blot analysis), Sigma). The membranes were washed with PBS-T and incubated with horseradish peroxidase-conjugated antirabbit IgG or anti-mouse IgG for 1 h. Following washing with PBS-T, immunoreactive bands were visualized by the ECL chemiluminescence system (Amersham Life Science, Buckinghamshire, UK).
Flow cytometry for DR4 and DR5
Cells were analysed for the surface expression of DR4 and DR5 by indirect staining with primary goat anti-human DR4 and DR5 (R&D systems), followed by phycoerythrin (PE)-conjugated rabbit anti-goat IgG (Sigma). Briefly, cells (5 Â 10 5 ) were stained with 200 ml PBS containing saturating amounts of anti-DR4 or anti-DR5 on ice for 30 min. After incubation, cells were washed twice, and reacted with PE-conjugated rabbit anti-goat IgG on ice for 30 min. After double washing with PBS, the expression of DR4 and DR5 was analysed by FACScan (Epics XL, Beckman Coulter). Figure 8 Effects of IFN-a on TRAIL-mediated transcriptional activity of NF-kB in HuH-7 and HepG2 cells. PNFkB-luc was cotransfected with pRL-CMV-luc into HuH-7 (a) and HepG2 (b) cells. After 6 h hours later, the cells were incubated with or without 1000 IU/ml of IFN-a for 36 h, followed by treatment with the indicated concentrations of TRAIL for 7 h. Luciferase activity in the cells was then analysed by dual-luciferase assay. Data represent the ratios of firefly-luc activity derived from pNFkB-luc over renilla-luc activity derived from pRL-CMV-luc relative to the control (no treatment), and are expressed as mean7s.d. of three separate experiments Enhancement of TRAIL-induced apoptosis by IFN-a M Shigeno et al
RNase protection assay
The RNase protection assay was performed using a RiboQuant Multi-Probe RNase Protection Assay System (PharMingen). According to the instructions provided by the manufacturer, hAPO3c (death receptors and death ligands) and hAPO5c (inhibitors of apoptosis) template sets, including a ribosomal protein L32 and a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) template as internal controls, were labeled with [a 32 P] UTP using T7 RNA polymerase. The labeled RNA probes were hybridized with 10 mg of total RNA from HuH-7 cells treated with or without 1000 IU/ml of IFN-a for 48 h. Samples were digested with RNase to remove singlestranded (nonhybridized) RNA. The remaining probes were resolved on 6% urea-polyacrylamide-bis-acrylamide gels. Gels were dried and analysed using an image analyser (BAS, Fuji Film Co., Tokyo).
Cell transfection and luciferase assay
The plasmids pNFkB-luc (Stratagene, La Jolla, CA, USA) containing four copies of the binding sequence of NF-kB and the firefly luciferase gene, and pRL-CMV-luc (Promega, Madison, WI, USA) containing the CMV immediate early enhancer/promoter and renilla luciferase gene were used in the assay. Cells were grown in 24-well multiplates in triplicate the day before transfection. In the next step, 200 ng of pNFkB-luc and 10 ng of pRL-CMV-luc were transfected into the cells by the lipofection method in serum-free medium. After a 6-h incubation, the medium was replaced with fresh medium containing 10% FBS with or without 1000 IU/ml of IFN-a, and the cells were incubated for 36 h, followed by treatment with varying concentrations of TRAIL for 7 h. Luciferase activity in the cells was then determined by a dual-luciferase reporter assay system and a TD-20/20 luminometer (Promega). In some experiments, pCR2FL; a flag/survivin fusion protein expression vector (Kobayashi et al., 1999) , kindly provided by Prof. T Tokuhisa (Department of Developmental Genetics, Chiba University) or pCR3.1, a vehicle vector (Invitrogen, Carlsbad, CA, USA), was transfected into HuH-7 cells cultured in 6-or 24-well multiplates.
Electrophoretic mobility shift assay (EMSA)
Cells were incubated in the presence or absence of 1000 IU/ml of IFN-a for 48 h, followed by treatment with or without Figure 9 Effect of IFN-a on DNA-binding activity of NF-kB induced by TRAIL in HuH-7 and HepG2 cells. (a) Nuclear extracts from HuH-7 cells incubated in the absence (lanes 1-6) or presence (lanes 7-12) of 50 ng/ml TRAIL for 2 h were subjected to EMSA using a 32 P-labeled NF-kB oligonucleotide probe. To identify the subunits of NF-kB, the nuclear extract was preincubated for 30 min with the rabbit polyclonal anti-p50 (lanes 2 and 8), anti-c-Rel (lanes 3 and 9) and anti-RelA (lanes 4 and 10). For analysis of the specific binding to the kB sequence, a 100-times molar excess of the nonradiolabeled NF-kB oligonucleotides (lanes 5 and 11) or AP-1 oligonucleotides (lanes 6 and 12) was added to the sample as a competitor. (b) Nuclear extracts from HuH-7 and HepG2 cells preincubated with (lanes 2, 4, 6 and 8) or without (lanes 1, 3, 5 and 7) 1000 IU/ml of IFN-a, followed by treatment with (lanes 3, 4, 7 and 8) or without (lanes 1, 2, 5 and 6) 50 ng/ml of TRAIL for 2 h were subjected to EMSA using a 32 P-labeled NF-kB oligonucleotide probe. Results shown are from one representative experiment from a total of three performed Enhancement of TRAIL-induced apoptosis by IFN-a M Shigeno et al 50 ng/ml of TRAIL for 2 h, and the nuclear extract was prepared as described previously (Nakao et al., 1999) . Rabbit polyclonal anti-human p50, anti-human c-Rel and anti-human RelA were purchased from Santa Cruz Biotechnology. The following double-stranded oligonucleotides were used as probes or competitors in the assays (only the sense strand is shown): NF-kB oligonucleotide, AGTTGAGGG-GACTTTCCCAGG; AP-1 oligonucleotide, CGCTTGAT-GAGTCAGCCGGAA. The probe was end-labeled with [g-32 P]ATP using T4 polynucleotide kinase. Nuclear extracts (4 mg) were incubated with 10 fmol of the labeled probe for 30 min at room temperature in the presence of 40 mm KCl, 20 mm HEPES (pH 7.9), 1 mm MgCl 2 , 0.1 mm EDTA, 1 mm dithiothreitol, 2 mg of poly (dI-dC), and 8% glycerol. The reaction mixture was electrophoresed on a 4% polyacrylamide gel containing 25 mm Tris-borate and 0.25 mm EDTA. Gels were dried and analysed using an image analyzer.
Caspase-8 activity
Caspase-8 activity was determined using the ApoAlert Caspase-8 Colorimetric Assay kit (Clontech Laboratories, Palo Alto, CA, USA). In brief, cell pellets obtained from 2 Â 10 6 cells were resuspended in 50 ml of chilled lysis buffer and incubated on ice for 10 min. The cell lysates were centrifuged at 12 000 r.p.m. at 41C for 3 min, and the supernatants were collected. Reaction buffer (50 ml) containing 10 mm dithiothreitol and 5 ml of 1 mm IETD-pNA (N-acetyl-Ile-Glu-ThrAsp-p-nitroaniline) substrate was added to the supernatants and incubated at 371C for 2 h in the dark. The absorbance of each sample was measured at 405 nm with a microtiter plate reader.
Abbreviations EMSA, electrophoretic mobility shift assay; FADD, Fasassociated death domain; FLIP, FLICE-inhibitory protein; IAP, inhibitor of apoptosis; IETD-pNA, N-acetyl-Ile-GluThr-Asp-p-nitroaniline; IFN-a, interferon-a; TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; XIAP, X-chromose-linked IAP.
